XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 60 filers reported holding XENON PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,145,623 | -27.4% | 121,359 | -67.5% | 0.76% | +57.6% |
| Q3 2021 | $5,707,000 | -88.9% | 373,510 | +35.3% | 0.48% | -86.2% |
| Q2 2021 | $51,412,000 | +848.2% | 276,130 | -48.3% | 3.48% | +602.4% |
| Q1 2019 | $5,422,000 | +91.2% | 533,655 | +18.7% | 0.50% | +54.7% |
| Q4 2018 | $2,836,000 | -43.4% | 449,484 | +18.4% | 0.32% | -44.3% |
| Q3 2018 | $5,009,000 | +24.0% | 379,484 | -13.6% | 0.58% | +3.2% |
| Q2 2018 | $4,039,000 | +500.1% | 439,034 | +92.5% | 0.56% | +480.2% |
| Q3 2017 | $673,000 | -6.3% | 228,029 | 0.0% | 0.10% | -21.3% |
| Q2 2017 | $718,000 | -45.3% | 228,029 | -30.5% | 0.12% | -52.3% |
| Q1 2017 | $1,312,000 | -48.1% | 328,029 | 0.0% | 0.26% | -59.9% |
| Q4 2016 | $2,526,000 | +36.8% | 328,029 | +43.9% | 0.64% | +112.3% |
| Q3 2016 | $1,847,000 | – | 228,029 | – | 0.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 266,961 | $10,277,999 | 12.45% |
| COMMODORE CAPITAL LP | 1,845,000 | $71,032,500 | 7.98% |
| Altium Capital Management LP | 228,000 | $8,778,000 | 6.64% |
| TLS Advisors LLC | 33,756 | $1,300 | 5.58% |
| GREAT POINT PARTNERS LLC | 530,000 | $20,405,000 | 3.99% |
| DAFNA Capital Management LLC | 280,538 | $10,800,713 | 2.95% |
| Paradigm Biocapital Advisors LP | 989,327 | $38,089,090 | 2.94% |
| Nan Fung Group Holdings Ltd | 114,380 | $4,403,630 | 2.81% |
| Avoro Capital Advisors LLC | 4,900,000 | $188,650,000 | 2.56% |
| Ghost Tree Capital, LLC | 185,000 | $7,122,500 | 2.35% |